Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Debt (2017 - 2026)

Aytu Biopharma has reported Total Debt over the past 14 years, most recently at $11.9 million for Q4 2025.

  • Quarterly Total Debt fell 15.29% to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2025, down 15.29% year-over-year, with the annual reading at $20.0 million for FY2025, 56.73% up from the prior year.
  • Total Debt was $11.9 million for Q4 2025 at Aytu Biopharma, down from $25.3 million in the prior quarter.
  • Over five years, Total Debt peaked at $25.3 million in Q3 2025 and troughed at $600000.0 in Q1 2021.
  • The 5-year median for Total Debt is $14.7 million (2022), against an average of $13.7 million.
  • Year-over-year, Total Debt crashed 96.55% in 2021 and then skyrocketed 2277.83% in 2022.
  • A 5-year view of Total Debt shows it stood at $1.3 million in 2021, then soared by 995.36% to $14.6 million in 2022, then rose by 9.44% to $16.0 million in 2023, then dropped by 12.55% to $14.0 million in 2024, then decreased by 15.29% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Total Debt are $11.9 million (Q4 2025), $25.3 million (Q3 2025), and $20.0 million (Q2 2025).